The Rationale for PARP Inhibition plus IO in Ovarian Cancer

Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.

Related Videos
View All
Related Content